GlassScriptPhysician profile
Philip A Mongelluzzo
NPI 1871563247
$5,481.31
in general payments reported to CMS, 2019-2025
35 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $105 · 2021: $81.78 · 2022: $703 · 2023: $641 · 2024: $2,246 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Education: $45.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.10 |
| Education | $45.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,426.26 | 2022-2025 | |
| Abbvie INC. | $930.53 | 2019-2025 | |
| Novo Nordisk INC | $706.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.82 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $310.07 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Qol Medical, LLC | $272.61 | 2024-2025 | Sucraid, Sucraid |
| Amgen INC. | $169.41 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $146.97 | 2024 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $131.61 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $124.37 | 2024-2025 | Rexulti |
| Pfizer INC. | $84.94 | 2019-2025 | |
| Astellas Pharma US INC | $78.67 | 2024-2025 | Veozah |
| Allergan, INC. | $60.02 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $57.18 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $49.13 | 2019-2025 | Mounjaro, Zepbound |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $46.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.37 | 2019 | |
| Mylan Specialty L.P. | $40.62 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $39.72 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $39.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $37.32 | 2025 | Opsumit, Uptravi |
| Lundbeck LLC | $34.99 | 2025 | Rexulti |
| Exact Sciences Corporation | $28.66 | 2025 | The Cologuard Plus Collection Kit |
| Grt US Holding, INC. | $22.34 | 2021 | |
| Sumitomo Pharma America, INC. | $21.89 | 2025 | Myfembree |
| Jazz Pharmaceuticals INC. | $21.63 | 2019 | |
| Mdd US Operations, LLC | $18.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.59 | 2020 | |
| Almatica Pharma LLC | $16.02 | 2025 | Loreev Xr |
| Dexcom, INC. | $15.64 | 2022 | |
| Neurocrine Biosciences, INC. | $14.71 | 2019 | |
| Corcept Therapeutics | $13.64 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $13.50 | 2019 | |
| Abbott Laboratories | $12.96 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Mongelluzzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.